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OBJECTIVE : The aim of this study was to determine the lymph node status in a large cohort of women with
endometrial cancer from the public health system who were referred to an oncology reference center in Brazil
to identify candidates for the omission of lymphadenectomy based on clinicopathological parameters.
METHODS : We retrospectively analyzed a cohort of 310 women with endometrial cancer (255 endometrioid,
40 serous, and 15 clear cell tumors) treated between 2009 and 2014. We evaluated the histological type, grade
(low vs. high), tumor size (cm), depth of myometrial invasion (p50%, 450%) and lymphovascular space
invasion to determine which factors were correlated with the presence of lymph node metastasis.
RESULTS : The factors related to lymph node involvement were tumor size (p=0.03), myometrial invasion
(po0.01), tumor grade (po0.01), and lymphovascular space invasion (po0.01). The histological type was not
associated with the nodal status (p=0.52). Only twelve of 176 patients (6.8%) had low-grade endometrioid
carcinoma, tumor size p2 cm and o50% myometrial infiltration.
CONCLUSIONS : The omission of lymphadenectomy based on the histological type, grade, tumor size and depth
of myometrial invasion is not likely to have a large impact on the surgical treatment of endometrial cancer in
our population because most patients present with large and advanced tumors. New strategies are proposed
that prioritize hysterectomy performed in a general hospital as soon as possible after diagnosis, followed by an
evaluation of the need for lymph node dissection at a reference center.
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’ INTRODUCTION
Endometrial cancer is among the most frequently diag-
nosed malignancies of the female genital tract in industria-
lized nations (1). Although this disease is 10 times more
common in developed countries than in the developing
world, the incidence of and the mortality related to
endometrial cancer have increased dramatically in under-
privileged regions in past decades, and this neoplasm will
certainly constitute a major health care problem in the near
future (2).
Since 1988, the international scientific agenda regarding
endometrial cancer has been dominated by a debate about
nodal dissection. Although there have been technical discus-
sions about the most appropriate surgical approach for
treating endometrial cancer, regional disparities in access to
proper oncologic therapies have rarely been discussed in the
literature (3,4). Intuitively, one may assume that insufficient
human resources and medical technology are available in the
developing world. The lack of professionals with advanced
surgical expertise and the ability to perform retroperitoneal
lymphadenectomy is evident. In addition, many cancer
institutions in the developing world cannot offer adequate
operative treatments to meet patient demand. This situation
poses major difficulties in implementing standard oncologic
therapies and results in unacceptable treatment delays that
may lead to tumor progression and can negatively impact
survival (5). Thus, the scientific discussion of lymphadenect-
omy in the developed world may be considered distant fromDOI: 10.6061/clinics/2015(07)02
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the realities of the great number of women in developing
countries who are affected by the disease (5).
Several algorithms have been designed to guide the
selective omission of nodal dissection in patients with
endometrial cancer (6–11). The Mayo Clinic criteria (12),
which are based on histological type, differentiation grade,
tumor size, and myometrial invasion, are the most com-
monly applied. The presence of lymphovascular space
invasion (LVSI) has also been used to predict lymph node
(LN) metastasis (13). Although this algorithm was indepen-
dently validated (10), it has never been tested in a large
cohort of women in Brazil.
Following the 2009 release of guidelines for the surgical
staging of endometrial cancer by the International Federation
of Gynecology and Obstetrics (FIGO) (14) and because of the
current lack of consensus regarding the importance of
retroperitoneal lymphadenectomy (9,15,16), our institution
initiated a protocol in 2009 in which all patients with clinical
disease are considered candidates for complete surgical
staging with pelvic and para-aortic nodal dissection,
independent of prognostic risk factors.
The primary study objective was to use the Mayo Clinic
algorithm to determine the percentage of patients in our
institution for whom LN dissection could be avoided. The
secondary objective was to determine whether these criteria
are as useful in Brazil as they were found to be in the
previous validation study (10).
’ PATIENTS AND METHODS
After receiving ethics review board approval (ICESP no.
394/13), we conducted a retrospective study of patients with
endometrial cancer who underwent primary surgical treat-
ment at the Instituto do Câncer do Estado de São Paulo,
Universidade de São Paulo, Brazil, between January 2009
and February 2014. We included all patients with histologi-
cally confirmed endometrial carcinoma (FIGO stages
Ia–IIIc2) and no evidence of extrapelvic disease on initial
imaging staging (computed tomography or magnetic reso-
nance imaging) who underwent primary operative therapy
that included total hysterectomy with bilateral salpingo-
oophorectomy. We excluded patients who had received
neoadjuvant therapies and those who did not undergo a
total hysterectomy with bilateral salpingo-oophorectomy.
The medical records of all patients were reviewed, and the
following epidemiologic and operative information was
collected: age at diagnosis, surgical route (laparoscopic,
laparotomic, or vaginal), and the magnitude of the procedure
(complete staging with pelvic and para-aortic LN dissection,
incomplete staging with only pelvic or para-aortic LN
dissection, or lack of nodal dissection). Pathological analyses
were performed at the institution’s central laboratory.
Tumors were classified according to the World Health
Organization criteria as endometrioid (endometrioid or
mucinous) or non-endometrioid (serous or clear cells).
Endometrioid tumors were classified according to FIGO
criteria (14) as low grade (1 or 2) or high grade (3). Non-
endometrioid histology was considered high grade. Data on
tumor size (p or 42 cm), the depth of myometrial invasion
(p50% or 450%), and LVSI were obtained from the
pathological descriptions.
The final tumor staging was established according to the
FIGO 2009 classification (14). The patients included in the
study were divided into two major groups according to their
surgical staging. Group 1 comprised women for whom
lymphadenectomy was omitted or who underwent incom-
plete nodal dissection for diverse reasons, including
poor clinical condition, massive LN involvement, or intrao-
perative complications. Group 2 comprised women who
underwent pelvic and para-aortic lymphadenectomy and who
were categorized as LN positive (LN+) or LN negative (LN-).
Statistical analysis
The associations between LN metastasis and histological
parameters, tumor size, myometrial invasion, tumor grade,
and LVSI were assessed using chi-squared tests. The
statistical analyses were performed using MedCalc for
Windows (version 11.5.0.0; MedCalc Software, Mariakerke,
Belgium), and p-values o0.05 were considered significant.
’ RESULTS
The cohort comprised 310 patients (134 [43%] in group 1
and 176 [57%] in group 2). The mean patient age was 64±
10.2 (range, 32–86) years. In group 1, no LN dissection was
performed in 119 (38%) patients, and only pelvic or para-
aortic LN dissection was performed in 15 (5%) patients. Most
(n=192 [62%]) of the surgeries were laparoscopic, and
laparotomy was performed in 138 (38%) patients.
According to the histological analysis, 255 (82.3%) tumors
were endometrioid, 40 (12.9%) were serous, and 15 (4.8%)
were clear cell tumors. Table 1 summarizes the pathological
characteristics of the patients in groups 1 and 2. No
differences in age, histology, grade, tumor size, myometrial
infiltration, or LVSI were observed between the groups
(Table 1).
Among the patients in group 2, the median numbers of
pelvic and para-aortic LNs dissected were 14 (range, 1–47)
and 9 (range, 1–41), respectively. Table 2 shows the patho-
logical features of the surgical specimens according to the
participant’s LN status. The risk of LN involvement was
related to the tumor size (p=0.03; OR 0.13 [0.01-0.90]), depth
of myometrial invasion (po0.01; OR 0.18 [0.07-0.44]), LVSI
(po0.01; OR 0.14 [0.06-0.33]), and grade (p=0.01; OR
0.39 [0.18-0,85]) but not to histological type (p=0.52; OR
0.77 [0.32-1.99]). Twelve of the 176 (6.8%) patients in group 2
fulfilled the Mayo Clinic criteria for the omission of LN
dissection (endometrioid carcinoma with tumor size p2 cm,
p50% depth of myometrial infiltration, and low grade).
’ DISCUSSION
Surgeons have not reached a consensus regarding the
advantages of LN dissection for all patients with endometrial
cancer. Almost three decades after FIGO recommended
including lymphadenectomy in the surgical treatment of
endometrial cancer, much doubt remains about the extension
and benefits of this procedure (15,17,21). Even in reference
centers, complete LN dissection increases morbidity, opera-
tive time, and treatment costs (22,23). Many algorithms have
been proposed to predict LN involvement and to stratify
patients according to their need for a lymphadenectomy
(12,24). The most commonly used parameters are histological
type, grade, tumor size, myometrial invasion (9), tumor
markers (25), LVSI (13), and imaging characteristics (26).
Mariani et al. (12) proposed the use of the Mayo Clinic
algorithm to predict LN involvement in endometrial cancer.
Patients with low-grade endometrioid carcinoma, tumor size
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o2 cm, andp50% myometrial invasion are considered to be
at low risk of LN involvement and are thus candidates for
lymphadenectomy omission. These criteria indicated that
lymphadenectomy was not required for 27% of patients (all
low risk) and 33% of endometrioid cases (12). Despite the
omission of lymphadenectomy, the 5-year cause-specific
survival rate was 99.0%. This intraoperative algorithm has
been validated in two independent studies (12,24)
Comparing our population to that examined by Mariani
et al. (12), we found that 20% vs. 18% of cases were classified
as the non-endometrioid histological subtype, 72% vs. 68% of
tumors were low grade, and 77% vs. 46% of tumors had
p50% myometrial invasion. In addition, only 11% of our
patients presented a tumor size p2 cm. Mariani et al. (12)
determined that 27% of all patients and 33% of patients with
endometrioid tumors fulfilled the criteria for lymphadenect-
omy omission; in contrast, only 6.8% of the patients in our
population fulfilled these criteria. Most of our patients
presented with deep myometrial invasion and large tumors;
thus, the use of the Mayo Clinic criteria is unlikely to have a
large impact on surgical treatment in a population such as
ours.
LVSI is another strong predictor of LN metastasis (13). In
the presence of LVSI, an overall recurrence rate of 17% has
been reported (27), along with a hazard ratio of 4.9 (p=0.000)
that increased to 8.8 (p=0.004) when the LNs were positive
(28). The estimated 5-year survival rates of patients with
stage IIIc endometrial cancer with and without LVSI are
50.9% and 93.3%, respectively (p=0.0024) (29). Thus, LVSI is
associated with a high risk of recurrence and poor overall
survival, even in the early stages of endometrial cancer (30).
The main characteristics of endometrial cancer in our
Brazilian population were large tumors, deep myometrial
invasion, and a high rate of LVSI. This presentation of more
advanced disease may be associated with difficulties in
providing timely oncologic treatment for all cases within the
Table 1 - Age and pathological characteristics of 310 patients with endometrial carcinoma.
Characteristic All patients Complete surgical staging
(group 2)
Incomplete surgical staging
(group 1)
p-value
Age (years), mean (range) 63 (32–86) 64 (32–86) 63 (36–85)
Histology 0.14
Endometrioid 255 (82.3%) 116 (86.6%) 140 (79.5%)
Non-endometrioid 55 (17.7%) 18 (13.4%) 36 (20.5%)
Tumor size 0.22
p2 cm 42 (13.5%) 22 (16.4%) 20 (11.4%)
42 cm 178 (57.4%) 70 (52.2%) 108 (61.3%)
Unknown 90 (29.0%) 42 (31.3%) 48 (27.3%)
Myometrial invasion 0.13
p50% 158 (53.0%) 77 (57.5%) 81 (46.0%)
450% 140 (46.9%) 53 (39.5%) 87 (49.4%)
Unknown 4 (3.0%) 8 (4.6%)
Tumor grade 0.25
Low (1–2) 222 (71.6%) 101 (75.4%) 121 (68.7%)
High (3 and non-endometrioid) 88 (28.4%) 33 (24.6%) 55 (31.3%)
LVSI 0.40
No 197 (63.6%) 89 (66.4%) 108 (61.3%)
Yes 104 (33.5%) 40 (29.8%) 64 (36.4%)
Unknown 9 (2.9%) 5 (3.7%) 4 (2.3%)
Data are presented as n (%) unless otherwise noted. LSVI, lymphovascular space invasion.
Table 2 - Tumor parameters according to lymph node status in 176 patients with surgically staged endometrial carcinoma.
Parameter All patients Lymph node
positive
Lymph node
negative
p-value OR (95% CI)
Histology 0.52 0.77 (0.32–1.99)
Endometrioid 140 (79.5%) 32 (76.2%) 108 (80.6%)
Non-endometrioid 36 (20.5%) 10 (23.8%) 26 (19.4%)
Tumor size 0.03 0.13 (0.01–0.90)
p2 cm 20 (11.4%) 1 (2.4%) 19 (14.2%)
42 cm 108 (61.3%) 31 (73.8%) 77 (57.5%)
Unknown 48 (27.3%) 10 (23.8%) 38 (28.3%)
Myometrial invasion o 0.01 0.18 (0.07–0.44)
p50% 81 (46.0%) 8 (19.0%) 73 (54.5%)
450% 87 (49.4%) 33 (78.6%) 54 (40.3%)
Unknown 8 (4.6%) 1 (2.4%) 7 (5.2%)
Tumor grade 0.01 0.39 (0.18–0.85)
Low (1–2) 121 (68.7%) 22 (52.4%) 99 (73.9%)
High (3 and non-endometrioid) 55 (31.3%) 20 (47.6%) 35 (26.1%)
LVSI o 0.01 0.14 (0.06–0.33)
No 108 (61.3%) 12 (27.3%) 96 (72.7%)
Yes 64 (36.4%) 30 (68.2%) 34 (25.8%)
Unknown 4 (2.3%) 2 (4.5%) 2 (1.5%)
Data are presented as n (%). OR, odds ratio; CI, confidence interval; LVSI, lymphovascular space invasion.
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public health system. New strategies are thus needed
to address the challenge of providing adequate treatment.
We believe that it is most important to consider offering early
hysterectomy with bilateral salpingo-oophorectomy to all
patients as soon as possible after diagnosis. LN dissection
should be postponed until patients have been evaluated at a
reference center.
Developing countries lack sufficient numbers of reference
centers that perform oncologic surgery. In Brazil, and likely
in many other countries, patients with endometrial cancer
have two options: (1) undergoing a simple hysterectomy and
salpingo-oophorectomy at a general hospital, in discordance
with the protocol proposed by FIGO, or (2) waiting for
several months until treatment can be provided at one of the
few reference centers. General obstetricians and gynecolo-
gists are discouraged from surgically treating endometrial
cancer, even in cases of clinical suspicion, because they are
not sufficiently trained in LN dissection. When patients
finally arrive at reference centers, the disease is often
advanced, and tumors are large; in such scenarios, discus-
sions about whether to perform LN dissection are not
relevant. In our opinion, the main issue is determining how
to reduce the interval between diagnosis and surgical
treatment at existing general hospitals.
The delayed diagnosis of endometrial cancer has been
demonstrated to impact survival rates. In a retrospective
study of 190 postmenopausal patients with symptomatic
endometrial cancer and 123 asymptomatic patients with
suspicious endometria detected with transvaginal ultra-
sound, the 5-year disease-free survival rates were 74% and
62% in patients with p8 weeks and416 weeks of bleeding,
respectively (31). Delayed surgical treatment can reasonably
be considered to have the greatest impact on patients with
cancer diagnoses compared with other patient groups. We
believe that efforts should be made to perform a hyster-
ectomy while the disease is still in an early stage with a low
probability of LN metastasis. For patients with early-stage
disease, LN dissection has no benefit; in fact, it increases
morbidity and mortality. Previous studies have shown that
LN dissection with customized adjuvant treatment has a
potential advantage only in patients with LN positivity
(32,33); even among these patients, the benefits of systematic
LN dissection are questionable (15).
To overcome current obstacles to the surgical treatment
of endometrial cancer in Brazil, we recently proposed a
two-step approach to the systematic management of the
condition (34). In this approach, women with type I endo-
metrial cancer undergo total extrafascial hysterectomy with
bilateral salpingo-oophorectomy but without nodal dissec-
tion upon diagnosis. Following this primary intervention, all
women are referred to cancer centers, where specialists
evaluate the clinical and pathological risk factors based on
the analysis of surgical specimens. Decisions about the need
for an eventual reoperation to perform retroperitoneal
lymphadenectomy are based on the risk of nodal metastasis.
We consider that an early simple hysterectomy performed
by a general gynecologist in a general hospital would be
more advantageous for these women than delayed, albeit
supposedly ideal, surgery. If necessary, lymphadenectomy is
performed in a tertiary hospital. A large, collaborative,
prospective study should be performed to evaluate the
impacts of this innovative strategy on morbidity, mortality,
and treatment cost in patients with endometrial cancer,
particularly in developing countries.
In conclusion, the prediction of LN involvement based on
histology, grade, tumor size p2 cm and p50% myometrial
invasion appears unlikely to have a large impact on surgical
treatment of endometrial cancer in the Brazilian population.
Our patients presented with larger and more advanced
tumors, generally associated with delayed treatment. To
address this situation in Brazil, we consider recommending
performing a hysterectomy at a general hospital as soon as
possible after diagnosis and later evaluating the need for LN
dissection at a reference center. However, prospective studies
to evaluate the morbidity, feasibility and cost of this
systematic two-step surgical treatment need to be conducted
before a national recommendation is made.
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